588,168 adults with type 2 diabetes: 139,546 started a GLP-1 drug 448,622 started an SGLT2 inhibitor Followed for up to 3 yearsAt 3 years, NAION was more frequent among people who started GLP-1 drugs: GLP-1 drugs: 39.1 cases per 10,000 persons SGLT2 inhibitors: 29.3 cases per 10,000 persons That works out to 6 to 10 extra cases per 10,000
It also makes your body more sensitive to insulin -- the hormone that controls your blood sugar
For individuals seeking therapeutic antioxidant support, particularly those with compromised digestive function, genetic variations affecting glutathione recycling, or significant oxidative stress burdens, injectable administration offers a more reliable pathway to achieving and maintaining optimal glutathione levels
A post-mortem study by Tang et al
This blend is not approved by the FDA for human or veterinary use
In vitro studies use a wide range of concentrations